Summit Therapeutics on the Cusp: A Dual-Action Lung Cancer Drug Faces its Moment of Truth
The High-Stakes Gamble: Summit's Vision vs. Akeso's Strategic Play with Ivonesimab
The Quiet Revolution: Bispecific Antibodies and the Shifting Landscape of Cancer Treatment